Magenta Therapeutics Shares Crashes As Dose-Limiting Toxicities Observed In Lead Blood Cancer Study

• Magenta Therapeutics Inc (NASDAQ: MGTA) has stopped dosing participants at the Cohort 4 dosing level (0.13 mg/kg) of the MGTA-117 Phase 1/2 Dose Escalation Trial in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

• The company plans to dose additional participants at the Cohort 3 dosing level (0.08 mg/kg).

• Three participants were dosed in Cohort 4, and dose-limiting toxicities (DLTs) were observed in the second and third dosed participants.

• The first participant completed the 21-day DLT observation period with no DLTs. The second-dosed participant in Cohort 4 experienced a Grade 4 Serious Adverse Event (SAE) (respiratory) considered possibly related to MGTA-117.

• This SAE was later determined to be a DLT and a Suspected Unexpected Serious Adverse Reaction (SUSAR) due to lung involvement.

• This participant also experienced Grade 4 elevated liver enzyme levels.

• Magenta plans to continue enrollment at the Cohort 3 dose level.

• As presented at the 2022 American Society of Hematology Annual Meeting, no DLTs were observed in the fifteen participants dosed in the first three Cohorts in the clinical trial.

• Price Action: MGTA shares are down 51.70% at $0.41 on the last check Tuesday.

See more from Benzinga

• Magenta Therapeutics Shares Surge After Encouraging Data From Blood Cancer Candidate At ASH Meeting

• Tesla's Market Share 'Decimated,' Backlog Has 'Collapsed To Nothing' — Why Institutional Investors Are 'V

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.